AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ImpediMed’s Positive Interim Study Results Give Hope to Millions of Breast Cancer Survivors

May 16, 2019

CARLSBAD, Calif. & BRISBANE, Australia--(BUSINESS WIRE)--May 16, 2019--



WHO: Professor Sheila Ridner, PhD, RN, FAAN, the Martha Rivers Ingram Professor of Nursing at Vanderbilt University School of Nursing, Principal Investigator, PREVENT trial.

WHAT: Pre-specified, interim results of the PREVENT trial demonstrate 95 percent reduction in lymphedema progression in patients monitored by L-DEX. The interim analysis followed the first 508 patients enrolled in the study through 12 months of follow up. Surveillance of women at risk for breast cancer–related lymphedema using bioimpedance spectroscopy was more effective in preventing lymphedema progression than traditional arm circumference measurement when each was combined with immediate compression therapy.

“These impressive interim results support routine clinical evaluation of breast cancer survivors in any clinical setting using the L-Dex score and early intervention,” says Dr. Ridner. “This gives hope to millions of survivors and is a practice-changer.”

The pre-specified, interim detailed results of the PREVENT trial were presented by Dr. Ridner at the 2019 Annual Meeting of the American Society of Breast Surgeons (ASBrS) and simultaneously published in Annals of Surgical Oncology, one of the leading journals in oncology and surgery. A copy of the manuscript is available here.

WHEN: Ongoing – June is Cancer Survivor Month

About ImpediMed

Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO ® for multiple indications, including heart failure and lymphedema, sold in select markets globally. Visit www.impedimed.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190516005651/en/

CONTACT: Schedule media interviews and appearances:

CPR Communications for ImpediMed: ndufour@cpronline.com/btedesco@cpronline.com

201.641.1911 x 54 / 14

KEYWORD: AUSTRALIA UNITED STATES NORTH AMERICA AUSTRALIA/OCEANIA CALIFORNIA

INDUSTRY KEYWORD: WOMEN HEALTH ONCOLOGY RADIOLOGY CONSUMER

SOURCE: ImpediMed

Copyright Business Wire 2019.

PUB: 05/16/2019 09:32 AM/DISC: 05/16/2019 09:32 AM

http://www.businesswire.com/news/home/20190516005651/en